Clinical Trial Detail

NCT ID NCT02414165
Title P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Tocagen Inc.
Indications

glioblastoma multiforme

Therapies

Bevacizumab

Lomustine

Toca 511 + Toca FC

Temozolomide

Age Groups: adult

No variant requirements are available.